ReNeuron makes changes to board and senior management

UK-based stem cell therapy company ReNeuron (AIM: RENE) is making changes to its board and senior management as it prepares for the next phase of development.

It is strengthening the executive management of the business with an equivalent reduction in size of the non-executive board. Sharon Grimster has been appointed as general manager for Wales. She has been working in the business for some time in senior development, and has many years of experience in similar roles at businesses including F-star, Antisoma and Celltech. Randolph Corteling is being promoted to head of research from his current role as head of cell biology. Dr Corteling will have day-to-day responsibility for all research activities, including development of the company’s exosome therapeutic platform.

The company is also finalizing the appointment of two further new senior management positions: chief medical officer and head of regulatory affairs.